Partnerships
Translational science is a team sport.
Kihealth Labs partners across the diagnostic value chain — with academic medical centers, pharmaceutical developers, disease foundations, and health systems — to accelerate the path from molecular signal to clinical impact.
Partner ecosystem
An interconnected network of translational partners.
Every InterceptIQ™ program is co-developed across academic medicine, pharmaceutical R&D, health systems, population-health registries, and open-science consortia.
Co-developed studies, biobank access, joint discovery.
Companion diagnostics, PD monitoring, trial enrichment.
Clinical deployment, RWE, payer engagement.
Screening cohorts, registries, public-health programs.
Consortia, foundations, federated science.
Academic Medical Centers
Co-developed clinical studies, biobank access, and joint biomarker discovery programs.
- ◆Harvard Medical School
- ◆Stanford Genomics
- ◆UCSF
- ◆Memorial Sloan Kettering
- ◆Mass General Hospital
- ◆Johns Hopkins
- ◆Karolinska Institutet
Pharmaceutical & Biotech
Companion diagnostic development, pharmacodynamic monitoring, and trial enrichment.
- ◆Top-3 global pharma (oncology)
- ◆Top-5 global pharma (immunology)
- ◆Multiple clinical-stage biotechs
- ◆Pre-IND advisory engagements
Research Consortia & Foundations
Open-science collaborations advancing the science of cell-free DNA and early detection.
- ◆JDRF
- ◆Stand Up To Cancer
- ◆Alzheimer's Disease Neuroimaging Initiative
- ◆Broad Institute
- ◆EMBL
Health Systems
Implementation partners for clinical deployment, real-world evidence, and payer engagement.
- ◆Integrated delivery networks
- ◆Academic specialty practices
- ◆International reference labs
For potential partners
We're selective. We're also actively looking.
If you lead a research program, a pharmaceutical development team, or a health system interested in translational diagnostics — we'd like to talk.